Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroidectomy | 13 | 2023 | 876 | 3.080 |
Why?
|
Thyroid Neoplasms | 21 | 2023 | 2267 | 2.620 |
Why?
|
Physicians, Women | 5 | 2021 | 483 | 1.620 |
Why?
|
Hypocalcemia | 2 | 2023 | 191 | 1.600 |
Why?
|
Thyroid Nodule | 10 | 2019 | 750 | 1.390 |
Why?
|
Awards and Prizes | 3 | 2021 | 375 | 1.250 |
Why?
|
Fibromatosis, Aggressive | 3 | 2015 | 118 | 1.210 |
Why?
|
Adenocarcinoma, Follicular | 4 | 2022 | 320 | 1.130 |
Why?
|
General Surgery | 8 | 2023 | 1630 | 0.920 |
Why?
|
beta Catenin | 3 | 2014 | 1057 | 0.840 |
Why?
|
Parathyroid Hormone | 4 | 2023 | 1799 | 0.800 |
Why?
|
Parathyroidectomy | 2 | 2013 | 234 | 0.730 |
Why?
|
Intestinal Neoplasms | 3 | 2014 | 319 | 0.720 |
Why?
|
Carcinoma, Papillary | 6 | 2022 | 779 | 0.700 |
Why?
|
Carcinoma | 5 | 2018 | 2361 | 0.690 |
Why?
|
Internship and Residency | 7 | 2023 | 5761 | 0.660 |
Why?
|
Job Satisfaction | 2 | 2019 | 536 | 0.610 |
Why?
|
Carcinoma, Papillary, Follicular | 1 | 2016 | 60 | 0.560 |
Why?
|
Hymecromone | 1 | 2015 | 9 | 0.520 |
Why?
|
Endocrinology | 1 | 2021 | 440 | 0.520 |
Why?
|
Adenocarcinoma, Papillary | 2 | 2012 | 84 | 0.500 |
Why?
|
Cytodiagnosis | 3 | 2018 | 433 | 0.500 |
Why?
|
Faculty, Medical | 2 | 2020 | 1179 | 0.500 |
Why?
|
Adenoma | 5 | 2018 | 2167 | 0.490 |
Why?
|
Parathyroid Neoplasms | 2 | 2018 | 244 | 0.490 |
Why?
|
Neoplasm Invasiveness | 5 | 2021 | 3603 | 0.490 |
Why?
|
Vitamin D Deficiency | 1 | 2023 | 1327 | 0.470 |
Why?
|
Hypoparathyroidism | 1 | 2014 | 120 | 0.450 |
Why?
|
Lymph Node Excision | 1 | 2019 | 1242 | 0.450 |
Why?
|
Leadership | 2 | 2021 | 1349 | 0.450 |
Why?
|
Mesenchymal Stem Cells | 2 | 2015 | 1618 | 0.430 |
Why?
|
src-Family Kinases | 2 | 2012 | 549 | 0.420 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2018 | 599 | 0.410 |
Why?
|
Hyaluronic Acid | 1 | 2015 | 486 | 0.400 |
Why?
|
Terminology as Topic | 1 | 2018 | 1548 | 0.390 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2013 | 155 | 0.390 |
Why?
|
Burnout, Professional | 1 | 2019 | 685 | 0.380 |
Why?
|
Estrogen Receptor beta | 2 | 2013 | 175 | 0.380 |
Why?
|
Sulindac | 1 | 2010 | 29 | 0.380 |
Why?
|
Oligonucleotides | 1 | 2014 | 572 | 0.380 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2011 | 126 | 0.370 |
Why?
|
Cell Proliferation | 5 | 2018 | 10455 | 0.360 |
Why?
|
Thyroid Gland | 5 | 2019 | 1169 | 0.350 |
Why?
|
Cell Nucleus | 1 | 2018 | 2965 | 0.350 |
Why?
|
Intraoperative Care | 1 | 2013 | 766 | 0.350 |
Why?
|
Authorship | 2 | 2022 | 268 | 0.330 |
Why?
|
Biopsy, Fine-Needle | 7 | 2019 | 1089 | 0.330 |
Why?
|
Lymph Nodes | 2 | 2021 | 3454 | 0.330 |
Why?
|
Societies, Medical | 4 | 2021 | 3739 | 0.310 |
Why?
|
Estrogen Receptor alpha | 2 | 2013 | 575 | 0.310 |
Why?
|
Tyrosine | 1 | 2012 | 1460 | 0.300 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2010 | 774 | 0.280 |
Why?
|
Genes, APC | 1 | 2007 | 159 | 0.280 |
Why?
|
Congresses as Topic | 2 | 2021 | 760 | 0.280 |
Why?
|
Postoperative Complications | 7 | 2023 | 15194 | 0.270 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2019 | 9122 | 0.270 |
Why?
|
Retrospective Studies | 21 | 2023 | 76631 | 0.270 |
Why?
|
Proto-Oncogene Proteins B-raf | 5 | 2023 | 2015 | 0.270 |
Why?
|
Calcium | 4 | 2023 | 5742 | 0.260 |
Why?
|
Specialties, Surgical | 2 | 2020 | 385 | 0.260 |
Why?
|
Humans | 63 | 2023 | 739398 | 0.250 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2018 | 735 | 0.250 |
Why?
|
Female | 44 | 2023 | 378853 | 0.250 |
Why?
|
Wound Healing | 2 | 2015 | 2768 | 0.250 |
Why?
|
Male | 39 | 2023 | 349022 | 0.240 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13635 | 0.240 |
Why?
|
Adrenalectomy | 2 | 2018 | 339 | 0.230 |
Why?
|
Endocrine Surgical Procedures | 1 | 2023 | 33 | 0.230 |
Why?
|
Melanoma | 2 | 2019 | 5446 | 0.230 |
Why?
|
Middle Aged | 30 | 2021 | 212863 | 0.220 |
Why?
|
Paget Disease, Extramammary | 1 | 2022 | 40 | 0.210 |
Why?
|
Sulfonamides | 2 | 2008 | 1934 | 0.200 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2010 | 2455 | 0.200 |
Why?
|
Precancerous Conditions | 1 | 2008 | 966 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2021 | 2507 | 0.190 |
Why?
|
Pyrazoles | 2 | 2008 | 1963 | 0.190 |
Why?
|
Surgical Wound Dehiscence | 1 | 2022 | 214 | 0.190 |
Why?
|
Mutation | 7 | 2023 | 29658 | 0.190 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2021 | 2102 | 0.180 |
Why?
|
Reoperation | 4 | 2021 | 4192 | 0.180 |
Why?
|
Adult | 27 | 2022 | 213394 | 0.180 |
Why?
|
Adenocarcinoma, Sebaceous | 1 | 2019 | 19 | 0.180 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2021 | 2933 | 0.180 |
Why?
|
Sebaceous Gland Neoplasms | 1 | 2019 | 37 | 0.180 |
Why?
|
Neoplasm Staging | 5 | 2021 | 10961 | 0.170 |
Why?
|
Aged, 80 and over | 13 | 2021 | 57650 | 0.170 |
Why?
|
Hydroxyprostaglandin Dehydrogenases | 1 | 2018 | 30 | 0.160 |
Why?
|
Students, Medical | 2 | 2023 | 1850 | 0.160 |
Why?
|
Faculty | 1 | 2021 | 376 | 0.160 |
Why?
|
Clinical Clerkship | 2 | 2023 | 528 | 0.160 |
Why?
|
Intestinal Mucosa | 2 | 2013 | 3036 | 0.160 |
Why?
|
Minority Groups | 2 | 2023 | 1197 | 0.160 |
Why?
|
Aged | 22 | 2022 | 162698 | 0.160 |
Why?
|
Tumor Cells, Cultured | 3 | 2016 | 6310 | 0.150 |
Why?
|
Professional Competence | 1 | 2020 | 448 | 0.150 |
Why?
|
False Negative Reactions | 2 | 2018 | 589 | 0.150 |
Why?
|
Axilla | 1 | 2019 | 588 | 0.150 |
Why?
|
Signal Transduction | 4 | 2021 | 23355 | 0.150 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2015 | 2936 | 0.140 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2018 | 144 | 0.140 |
Why?
|
Ultrasonography | 8 | 2019 | 5941 | 0.140 |
Why?
|
Follow-Up Studies | 6 | 2019 | 38942 | 0.140 |
Why?
|
Lymphatic Metastasis | 3 | 2019 | 2897 | 0.140 |
Why?
|
Skin Transplantation | 1 | 2022 | 1073 | 0.140 |
Why?
|
Chemoprevention | 1 | 2018 | 323 | 0.130 |
Why?
|
Prognosis | 8 | 2023 | 28901 | 0.130 |
Why?
|
Technetium Tc 99m Sestamibi | 2 | 2018 | 177 | 0.130 |
Why?
|
Cyclooxygenase 2 | 1 | 2018 | 612 | 0.130 |
Why?
|
ras Proteins | 2 | 2018 | 1062 | 0.130 |
Why?
|
United States | 7 | 2022 | 69573 | 0.130 |
Why?
|
Monitoring, Intraoperative | 1 | 2021 | 954 | 0.130 |
Why?
|
Education, Medical, Undergraduate | 2 | 2023 | 999 | 0.130 |
Why?
|
Colonic Neoplasms | 1 | 2007 | 2530 | 0.130 |
Why?
|
Hyaluronoglucosaminidase | 1 | 2015 | 133 | 0.120 |
Why?
|
Glucuronosyltransferase | 1 | 2015 | 128 | 0.120 |
Why?
|
Hepatocyte Nuclear Factor 3-beta | 1 | 2013 | 67 | 0.120 |
Why?
|
GPI-Linked Proteins | 1 | 2015 | 433 | 0.110 |
Why?
|
Workplace | 1 | 2019 | 837 | 0.110 |
Why?
|
Radionuclide Imaging | 2 | 2018 | 2028 | 0.110 |
Why?
|
Technetium | 1 | 2013 | 336 | 0.110 |
Why?
|
Bronchogenic Cyst | 1 | 2012 | 29 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7274 | 0.110 |
Why?
|
Survival Rate | 2 | 2019 | 12761 | 0.110 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2016 | 1674 | 0.100 |
Why?
|
Overweight | 1 | 2023 | 2355 | 0.100 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 705 | 0.100 |
Why?
|
Maximum Tolerated Dose | 1 | 2014 | 888 | 0.100 |
Why?
|
Toll-Like Receptor 4 | 1 | 2015 | 560 | 0.100 |
Why?
|
Ultrasonography, Doppler | 1 | 2013 | 460 | 0.100 |
Why?
|
Qualitative Research | 1 | 2019 | 2656 | 0.100 |
Why?
|
Stromal Cells | 1 | 2016 | 1350 | 0.100 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1522 | 0.100 |
Why?
|
Education, Medical, Graduate | 4 | 2023 | 2275 | 0.090 |
Why?
|
Shock, Hemorrhagic | 1 | 2012 | 220 | 0.090 |
Why?
|
Phosphorylation | 2 | 2012 | 8416 | 0.090 |
Why?
|
Pheochromocytoma | 1 | 2012 | 337 | 0.090 |
Why?
|
Bariatric Surgery | 1 | 2019 | 935 | 0.090 |
Why?
|
Patient Selection | 2 | 2018 | 4211 | 0.090 |
Why?
|
Receptor, erbB-2 | 1 | 2019 | 2370 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2018 | 5502 | 0.080 |
Why?
|
Obesity | 2 | 2023 | 12643 | 0.080 |
Why?
|
Sex Factors | 2 | 2019 | 10398 | 0.080 |
Why?
|
Accreditation | 2 | 2022 | 448 | 0.080 |
Why?
|
Prospective Studies | 8 | 2022 | 53037 | 0.080 |
Why?
|
Cell Adhesion Molecules | 1 | 2015 | 1599 | 0.080 |
Why?
|
Adiposity | 1 | 2018 | 1801 | 0.080 |
Why?
|
Hypercalcemia | 1 | 2011 | 405 | 0.080 |
Why?
|
Quality Improvement | 1 | 2023 | 3730 | 0.080 |
Why?
|
Intestinal Polyps | 1 | 2008 | 100 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3606 | 0.080 |
Why?
|
Immunohistochemistry | 2 | 2011 | 11347 | 0.080 |
Why?
|
Body Mass Index | 2 | 2022 | 12655 | 0.070 |
Why?
|
High-Throughput Screening Assays | 1 | 2012 | 953 | 0.070 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2008 | 370 | 0.070 |
Why?
|
Mice, Inbred C57BL | 4 | 2014 | 21863 | 0.070 |
Why?
|
Adenocarcinoma | 1 | 2023 | 6318 | 0.070 |
Why?
|
Transforming Growth Factor beta | 1 | 2013 | 1997 | 0.070 |
Why?
|
Enterocytes | 1 | 2007 | 225 | 0.070 |
Why?
|
Metabolome | 1 | 2012 | 881 | 0.070 |
Why?
|
Colon | 1 | 2013 | 1771 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2018 | 13880 | 0.060 |
Why?
|
Retroperitoneal Space | 2 | 2018 | 171 | 0.060 |
Why?
|
Thiazoles | 1 | 2012 | 1488 | 0.060 |
Why?
|
Intestines | 1 | 2014 | 1919 | 0.060 |
Why?
|
Fellowships and Scholarships | 2 | 2023 | 1058 | 0.060 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 4791 | 0.060 |
Why?
|
Cell Line, Tumor | 2 | 2011 | 16646 | 0.060 |
Why?
|
Cell Movement | 1 | 2016 | 5221 | 0.060 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2006 | 320 | 0.060 |
Why?
|
Cohort Studies | 6 | 2022 | 40389 | 0.060 |
Why?
|
Neuroendocrine Tumors | 1 | 2010 | 593 | 0.060 |
Why?
|
Placebos | 1 | 2008 | 1678 | 0.060 |
Why?
|
Clinical Competence | 3 | 2023 | 4671 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3571 | 0.060 |
Why?
|
Young Adult | 7 | 2020 | 56255 | 0.060 |
Why?
|
Radiopharmaceuticals | 1 | 2013 | 2687 | 0.060 |
Why?
|
Up-Regulation | 1 | 2012 | 4205 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2022 | 5632 | 0.050 |
Why?
|
Committee Membership | 1 | 2020 | 15 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4539 | 0.050 |
Why?
|
Mitotic Index | 1 | 2021 | 171 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2018 | 14740 | 0.050 |
Why?
|
Sex Ratio | 1 | 2020 | 110 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2727 | 0.050 |
Why?
|
Adolescent | 4 | 2019 | 85405 | 0.050 |
Why?
|
Risk Factors | 3 | 2022 | 71974 | 0.050 |
Why?
|
Pyrimidines | 1 | 2012 | 2918 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15153 | 0.040 |
Why?
|
Estrogens | 1 | 2007 | 1561 | 0.040 |
Why?
|
Risk | 3 | 2019 | 9684 | 0.040 |
Why?
|
Feedback | 1 | 2023 | 788 | 0.040 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2021 | 657 | 0.040 |
Why?
|
Gene Fusion | 1 | 2021 | 371 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4832 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2022 | 699 | 0.040 |
Why?
|
Mice | 4 | 2014 | 81002 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2020 | 62693 | 0.040 |
Why?
|
Necrosis | 1 | 2021 | 1643 | 0.040 |
Why?
|
Animals | 5 | 2014 | 168368 | 0.040 |
Why?
|
Phenotype | 3 | 2020 | 16301 | 0.030 |
Why?
|
Career Choice | 1 | 2022 | 742 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2021 | 6871 | 0.030 |
Why?
|
Preoperative Period | 1 | 2018 | 546 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 10945 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6516 | 0.030 |
Why?
|
Culture Media, Conditioned | 1 | 2016 | 532 | 0.030 |
Why?
|
Mentors | 1 | 2020 | 632 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18003 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2974 | 0.030 |
Why?
|
Mice, Transgenic | 1 | 2007 | 9734 | 0.030 |
Why?
|
Blood Loss, Surgical | 1 | 2018 | 658 | 0.030 |
Why?
|
Aberrant Crypt Foci | 1 | 2013 | 12 | 0.030 |
Why?
|
Rats | 1 | 2010 | 24270 | 0.030 |
Why?
|
Anthropometry | 1 | 2018 | 1344 | 0.030 |
Why?
|
Perception | 1 | 2020 | 1177 | 0.030 |
Why?
|
Paneth Cells | 1 | 2013 | 100 | 0.030 |
Why?
|
Intra-Abdominal Fat | 1 | 2018 | 590 | 0.030 |
Why?
|
Smad4 Protein | 1 | 2013 | 162 | 0.030 |
Why?
|
Hypothyroidism | 1 | 2018 | 659 | 0.030 |
Why?
|
Quality of Life | 1 | 2014 | 12640 | 0.030 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 1 | 2012 | 44 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2016 | 1343 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2010 | 5213 | 0.030 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2012 | 174 | 0.030 |
Why?
|
Program Evaluation | 1 | 2020 | 2484 | 0.030 |
Why?
|
GTP Phosphohydrolases | 1 | 2015 | 508 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2019 | 20676 | 0.030 |
Why?
|
Learning | 1 | 2020 | 1695 | 0.020 |
Why?
|
Gastric Bypass | 1 | 2019 | 809 | 0.020 |
Why?
|
Models, Biological | 1 | 2007 | 9609 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2013 | 1883 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 12948 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2007 | 11460 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2749 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2018 | 2026 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2015 | 2373 | 0.020 |
Why?
|
Hedgehog Proteins | 1 | 2013 | 774 | 0.020 |
Why?
|
Delayed Diagnosis | 1 | 2012 | 429 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2018 | 5058 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9846 | 0.020 |
Why?
|
Marriage | 1 | 2009 | 336 | 0.020 |
Why?
|
Algorithms | 1 | 2008 | 13872 | 0.020 |
Why?
|
Risk Assessment | 2 | 2019 | 23294 | 0.020 |
Why?
|
Lipoxygenase | 1 | 2006 | 74 | 0.020 |
Why?
|
Receptors, Prostaglandin | 1 | 2006 | 57 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 4182 | 0.020 |
Why?
|
Laparoscopy | 1 | 2018 | 2091 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13402 | 0.020 |
Why?
|
Pancreatectomy | 1 | 2010 | 799 | 0.020 |
Why?
|
Probability | 1 | 2010 | 2500 | 0.020 |
Why?
|
World Health Organization | 1 | 2010 | 1321 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2022 | 21694 | 0.010 |
Why?
|
Time Factors | 2 | 2018 | 40050 | 0.010 |
Why?
|
Dinoprostone | 1 | 2006 | 597 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3510 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2015 | 4555 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 1997 | 5830 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2012 | 2039 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 6361 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2010 | 6370 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13237 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 24714 | 0.010 |
Why?
|
Databases, Factual | 1 | 2015 | 7690 | 0.010 |
Why?
|
Stem Cells | 1 | 2013 | 3566 | 0.010 |
Why?
|
HIV-1 | 1 | 1997 | 6931 | 0.010 |
Why?
|
Family | 1 | 2009 | 3141 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2015 | 7862 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2006 | 4935 | 0.010 |
Why?
|
HIV Long Terminal Repeat | 1 | 1997 | 88 | 0.010 |
Why?
|
Life Style | 1 | 2009 | 3817 | 0.010 |
Why?
|
Gene Products, tat | 1 | 1997 | 120 | 0.010 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 1997 | 126 | 0.010 |
Why?
|
Survival Analysis | 1 | 2010 | 10247 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15036 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1997 | 1088 | 0.010 |
Why?
|
Transcription Factor RelA | 1 | 1997 | 276 | 0.010 |
Why?
|
Proviruses | 1 | 1997 | 316 | 0.010 |
Why?
|
NFATC Transcription Factors | 1 | 1997 | 380 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2009 | 3844 | 0.010 |
Why?
|
Gene Expression Regulation, Viral | 1 | 1997 | 441 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20055 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15511 | 0.010 |
Why?
|
Registries | 1 | 2010 | 8039 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2013 | 6726 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1997 | 2256 | 0.010 |
Why?
|
Hypertension | 1 | 2012 | 8431 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 35326 | 0.010 |
Why?
|
DNA, Viral | 1 | 1997 | 2223 | 0.010 |
Why?
|
Phylogeny | 1 | 1997 | 2789 | 0.010 |
Why?
|
NF-kappa B | 1 | 1997 | 2502 | 0.010 |
Why?
|
Binding Sites | 1 | 1997 | 6113 | 0.010 |
Why?
|
Base Sequence | 1 | 1997 | 12804 | 0.000 |
Why?
|
Promoter Regions, Genetic | 1 | 1997 | 5863 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1997 | 18125 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 1997 | 7709 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 1997 | 9622 | 0.000 |
Why?
|
Transcription Factors | 1 | 1997 | 12120 | 0.000 |
Why?
|